Buprenorphine / Naloxone

DRUG2 trials

Sponsors

NanoSHIFT LLC, AstraZeneca

Conditions

HealthyOpioid Use Disorder

Phase 1

Drug-Drug Interaction and Safety of AZD4041 Study (Part 1) and Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of AZD4041 Study in Opioid Use Disorder (Part 2).

TerminatedNCT06406400

AstraZenecaOpioid Use Disorder

Start: 2024-05-13End: 2024-07-31Updated: 2025-03-26

Unknown Phase

A Single-Dose Study of an Investigational Capsule Formulation of 2 mg/0.5 mg Buprenorphine/Naloxone

CompletedNCT00880841

NanoSHIFT LLCHealthy

Start: 2009-04-30End: 2009-05-31Updated: 2017-06-23